At the same time, NKTR-255 induces sustained receptor engagement, efficiently and durably stimulates proliferation and activation of NK cells and CD8+ T cells, and shows superior anti-tumor activity to rhIL-15 (Miyazaki et al., 2021). Here, CD8A is linked to neoplasm.